Section Arrow
MAIA.NYSE-M
- MAIA Biotechnology
Quotes are at least 15-min delayed:2026/01/05 06:41 EST
Pre Market
Last
 1.6
0 (0.00%)
Bid
1.6
Ask
1.65
High 1.64 
Low 1.6 
Volume 141 
Regular Hours (Closed)
Last
 1.6
+0.07 (+4.58%)
Day High 
1.66 
Prev. Close
1.53 
1-M High
1.75 
Volume 
835.72K 
Bid
1.6
Ask
1.65
Day Low
1.535 
Open
1.6 
1-M Low
1.07 
Market Cap 
56.29M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.36 
20-SMA 1.33 
50-SMA 1.23 
52-W High 2.74 
52-W Low 0.87 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
-0.74/-0.69
Enterprise Value
56.29M
Balance Sheet
Book Value Per Share
0.00
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
OTLKOutlook Therapeutics0.66-0.92-58.23%0.58PE
Pre Market 0.6868 +0.0268 +4.06%
MREOMereo BioPharma Group plc0.5104+0.0937+22.49%-- 
Pre Market 0.5267 +0.0163 +3.19%
SLSSELLAS Life Sciences Group4.35+0.58+15.38%-- 
Pre Market 4.76 +0.41 +9.43%
ASBPAspire Biopharma Holdings Inc.0.1369+0.005+3.79%-- 
Pre Market 0.14635 +0.00945 +6.90%
RXRXRecursion Pharmaceuticals4.2+0.11+2.69%-- 
Pre Market 4.29 +0.09 +2.14%
Industry overview quotes are at least 15 minutes delayed
Business Description
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.